Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023 ACCESSWIRE - Wed Oct 18, 2023

- Live video webcast interactive Q&A with participating companies -

EVFM : 0.0100 (unch)
GRI : 0.6890 (+7.82%)
MBRX : 2.83 (+5.99%)
XBIO : 4.01 (+0.57%)
AREC : 1.0800 (+1.89%)
CNSP : 0.1300 (+5.18%)
NVNO : 3.30 (-2.08%)
PALI : 2.44 (unch)
Moleculin to Participate in the Virtual Investor Ask the CEO Conference PR Newswire - Wed Oct 11, 2023

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...

MBRX : 2.83 (+5.99%)
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including...

MBRX : 2.83 (+5.99%)
Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107) PR Newswire - Thu Sep 21, 2023

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including...

MBRX : 2.83 (+5.99%)
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin PR Newswire - Mon Sep 18, 2023

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 2.83 (+5.99%)
Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting PR Newswire - Thu Sep 14, 2023

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 2.83 (+5.99%)
Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire - Tue Sep 5, 2023

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 2.83 (+5.99%)
Moleculin Reports Second Quarter 2023 Financial Results PR Newswire - Fri Aug 11, 2023

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 2.83 (+5.99%)
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones PR Newswire - Thu Aug 10, 2023

– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML...

MBRX : 2.83 (+5.99%)
Moleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...

MBRX : 2.83 (+5.99%)

Barchart Exclusives

1 AI Stock to Buy and Hold for Long-Term Growth Barchart - Thu Nov 21, 7:18PM CST
Pure Storage stands out in AI data storage, bolstered by a new partnership with CoreWeave and a solid financial track record, making it an intriguing stock for AI-focused investors Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot